Oxford Biomedica

Oxford Biomedica (OXB) is a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company was founded in 1995 as a spin-out from the University of Oxford by Professor Alan Kingsman and Dr. Susan Kingsman, leveraging their expertise in virology and gene expression. It went public via an initial public offering on the Alternative Investment Market in 1996.

OXB operates on a business-to-business (B2B) model, serving pharmaceutical and biotechnology companies ranging from small startups to large corporations. The company's core business revolves around providing viral vector development and manufacturing services, which are crucial components for its clients' gene and cell therapy products. This includes expertise in lentivirus, adeno-associated virus (AAV), and adenovirus vectors. Its revenue is generated through these contract services, supporting clients from early-stage development and clinical trials to full-scale commercial manufacturing. The company has recently transformed into a 'pure-play' CDMO to focus entirely on these client-centric services, a move that included significant operational streamlining.

The company's key offerings include its proprietary LentiVector™ platform and the inAAVate™ platform for AAV vectors, providing end-to-end solutions from process development to manufacturing. OXB has established numerous high-profile partnerships with companies like Novartis, Sanofi, and GSK. A notable collaboration was with the Jenner Institute and AstraZeneca to manufacture the COVID-19 vaccine. The company maintains state-of-the-art facilities in the UK, France, and the US to serve its global client base.

Keywords: cell and gene therapy, CDMO, viral vector manufacturing, lentiviral vectors, adeno-associated virus, AAV, pharmaceutical biotechnology, drug development, process development, GMP manufacturing, gene-based medicines, LentiVector, clinical trials, biopharmaceutical services, contract manufacturing, therapeutic delivery, vector development, oncology, neurodegenerative diseases, ocular diseases